BridgeMD
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
EU CTIS ID: 2024-513647-86-00
What this study is testing
To evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- -Patients (men or women) aged 18 years old and over -Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract, eye, nerves and brain tissues, respiratory tract, cardio-vascular disorders, genito-urinary tract including kidney, musculo-skeletal tissues. Skin involvement is mandatory in order to be able to compare involved and non involved tissue -Signed informed consent The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert assessment of the Scientific committee meeting (cf paragraph 10.2). The disease alters significantly quality of life. The impairment of quality of life will be assessed based on the investigator’s assessment. The disease has been resistant to at least two prior lines of treatment [for example : Hydroxychloroquine, Chloroquine, Colchicine, Methotrexate, Ciclosporine, Azathioprine, Mycophenolate mofetil, Disulone, Corticosteroids (prednisone, prednisolone, dexamethasone, methylprednisolone…)].
You likely can't join if
- -Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy -Patients refusing biopsies -Pregnancy -Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method -Breastfeeding -Patients presenting disease needing urgent therapeutic measures -Patients without health insurance or social security -Participation in another interventional trial -Patients under legal protection -Patients unable to respect the wash out delay of previously taken medications before biopsy and before treatment initiation -Patients with contra-indications to treatments
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.